Stock VIGL VIGIL NEUROSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Vigil Neuroscience, Inc.

Equities

VIGL

US92673K1088

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
2.71 USD +5.04% Intraday chart for Vigil Neuroscience, Inc. -3.90% -19.82%
04-17 Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting CI
03-26 Wedbush Trims Vigil Neuroscience Price Target to $22 From $23, Maintains Outperform Rating MT

Business Summary

Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.

Number of employees: 69

Managers

Managers TitleAgeSince
Ivana Magovcevic-Liebisch CEO
 Chief Executive Officer 55 30/06/20
Jennifer Ziolkowski DFI
 Director of Finance/CFO 50 30/06/20
Kelly Neelon CTO
 Chief Tech/Sci/R&D Officer - -
David Gray CTO
 Chief Tech/Sci/R&D Officer 50 26/02/23
Sharon Morani COO
 Chief Operating Officer - 31/05/22
Kevin Durfee CTO
 Chief Tech/Sci/R&D Officer - -
Samantha Zappia LAW
 General Counsel - -
Pam Meneses AUD
 Comptroller/Controller/Auditor - -
Park Guo AUD
 Comptroller/Controller/Auditor - -
Christopher Verni LAW
 General Counsel 49 19/04/22

Members of the board

Members of the board TitleAgeSince
Ivana Magovcevic-Liebisch CEO
 Chief Executive Officer 55 30/06/20
Mary Thistle BRD
 Director/Board Member 64 17/04/22
Cheryl Blanchard BRD
 Director/Board Member 59 31/10/20
Suzanne Bruhn BRD
 Director/Board Member 60 26/07/22
Bruce Booth CHM
 Chairman 49 31/05/20
Stefan Vitorovic BRD
 Director/Board Member 39 31/07/21
Samantha Haeberlein BRD
 Director/Board Member - 07/05/23
Gerhard Koenig BRD
 Director/Board Member 63 30/11/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 37,628,635 34,147,189 ( 90.75 %) 44,323 ( 0.1178 %) 90.75 %

Shareholders

NameEquities%Valuation
Atlas Venture Life Science Advisors LLC
15.82 %
5,836,874 15.82 % 20 M $
VV Manager LLC
13.60 %
5,015,929 13.60 % 17 M $
Northpond Ventures LLC
11.43 %
4,214,498 11.43 % 14 M $
AMGEN INC.
8.693 %
3,206,281 8.693 % 11 M $
Citadel Securities GP LLC
5.861 %
2,161,902 5.861 % 7 M $
BVF, Inc.
4.917 %
1,813,633 4.917 % 6 M $
Artal Group SA
4.910 %
1,811,191 4.910 % 6 M $
Invus Public Equities Advisors LLC
4.910 %
1,811,191 4.910 % 6 M $
Deep Track Capital LP
4.324 %
1,594,931 4.324 % 5 M $
Hatteras Venture Partners
4.236 %
1,562,578 4.236 % 5 M $

Company contact information

Vigil Neuroscience, Inc.

100 Forge Road Suite 700

02472, Watertown

+

http://www.vigilneuro.com
address Vigil Neuroscience, Inc.(VIGL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.71 USD
Average target price
16.75 USD
Spread / Average Target
+518.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VIGIL NEUROSCIENCE, INC. Stock Vigil Neuroscience, Inc.
-19.82% 102M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VIGL Stock
  4. Company Vigil Neuroscience, Inc.